Outset Medical jumps on Q4 revenue beat, strong outlook

Outset Medical

17/02/2022 15:55

** Shares of portable dialysis machine maker  OM.O  rise
11.2% to $38.05
    ** Co's Q4 revenue of $28.2 mln surpasses Refinitiv IBES
estimates of $26.4 mln, driven by strong demand for its Tablo
dialysis machine, which can be used in hospitals as well as at
home  urn:newsml:reuters.com:*:nBwbdrBHka
    ** Forecasts 2022 revenue between $142 mln and $150 mln, an
about 38% to 46% jump from last year
    ** OM, during its conference call, said it sees growth in
the use of Tablo for acute care and home use in 2022
    ** SVB Leerink says it is confident in OM's long-term growth
prospects and raises its 2022 revenue estimate for co to $147.8
mln from $146.6 mln
    "OM can drive meaningful upside to even our now-higher sales
estimates in 2022 and beyond," says brokerage; rates the stock
"outperform"
    ** Stock down 17.4% YTD, including session's moves

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))